Autonomic Nervous System Drugs — MCQs

Autonomic Nervous System Drugs Indian Medical PG Practice Questions and MCQs

Question 131: The use of succinylcholine is not contraindicated in which of the following conditions?

A. Tetanus
B. Closed head injury
C. Cerebral stroke
D. Hepatic failure (Correct Answer)

Explanation: **Explanation:** The core concept behind the contraindications of **Succinylcholine (SCh)**, a depolarizing neuromuscular blocker, is its tendency to cause **hyperkalemia** and increase **intracranial pressure (ICP)**. **Why Hepatic Failure is the Correct Answer:** Succinylcholine is metabolized by **pseudocholinesterase** (plasma cholinesterase), which is synthesized in the liver. In hepatic failure, levels of this enzyme may be low, leading to a **prolonged duration of action** (apnea). However, this is a *precaution* rather than an absolute contraindication. SCh does not worsen the underlying liver disease, nor does liver disease trigger the life-threatening hyperkalemic response seen in the other options. **Why the other options are Incorrect:** * **Tetanus & Cerebral Stroke (C):** These conditions involve upper motor neuron lesions or prolonged immobilization. This leads to the **upregulation of extrajunctional nicotinic receptors**. When SCh acts on these receptors, it causes massive potassium release from muscles, leading to severe, potentially fatal **hyperkalemia** and cardiac arrest. * **Closed Head Injury (B):** SCh causes fasciculations that can increase **intracranial pressure (ICP)** and intraocular pressure. In a head injury where ICP is already compromised, SCh is generally avoided to prevent secondary brain injury. **NEET-PG High-Yield Pearls:** 1. **Drug of Choice:** SCh is the drug of choice for **Rapid Sequence Induction (RSI)** due to its fastest onset (30-60s) and shortest duration (5-10 mins). 2. **Malignant Hyperthermia:** SCh is a notorious trigger; the antidote is **Dantrolene**. 3. **Phase II Block:** Occurs with high doses or continuous infusion, where the block behaves like a non-depolarizing one. 4. **Genetic Variation:** Patients with atypical pseudocholinesterase (detected by **Dibucaine number**) experience prolonged paralysis after SCh administration.

Question 132: Therapeutic use of acetylcholine is not possible because it is -

A. Highly protein bound
B. Rapidly degraded (Correct Answer)
C. Rapidly excreted
D. Orally ineffective

Explanation: **Explanation:** Acetylcholine (ACh) is the primary neurotransmitter of the parasympathetic nervous system, but it has **no clinical therapeutic utility** primarily because it is **rapidly degraded**. **1. Why "Rapidly Degraded" is correct:** ACh is a substrate for two major enzymes: **Acetylcholinesterase (AChE)**, found at synaptic clefts, and **Butyrylcholinesterase (Pseudocholinesterase)**, found in the plasma and liver. These enzymes hydrolyze ACh within milliseconds of administration. Consequently, even when given intravenously, it cannot reach target receptors in sufficient concentrations or for a long enough duration to produce a meaningful clinical effect. Furthermore, it lacks receptor selectivity, acting on both Muscarinic and Nicotinic receptors throughout the body. **2. Why other options are incorrect:** * **Highly protein bound:** ACh is a small, polar quaternary ammonium compound; it does not show significant plasma protein binding. * **Rapidly excreted:** While it is cleared quickly, the rate-limiting step for its inactivity is metabolic hydrolysis, not renal excretion. * **Orally ineffective:** While true (it is destroyed by gastric acid and esterases in the gut), this is not the primary reason it isn't used. Even if given parenterally, its rapid degradation in the blood renders it useless. **High-Yield Clinical Pearls for NEET-PG:** * **Synthetic Analogs:** To overcome rapid degradation, synthetic choline esters like **Bethanechol** and **Carbachol** were developed. They are resistant to AChE and have a longer duration of action. * **Miochol-E:** A stabilized form of ACh is used intraocularly *only* during ophthalmic surgery (e.g., cataract surgery) for immediate miosis, as it can be applied directly to the site of action. * **Structure:** ACh is a quaternary ammonium compound, meaning it is permanently charged and **cannot cross the Blood-Brain Barrier (BBB)**.

Question 133: What is the most common drug used for prophylaxis of migraine?

A. Sumatriptan
B. Propranolol (Correct Answer)
C. Valproate
D. Flunarizine

Explanation: **Explanation:** **Propranolol** is considered the **first-line drug of choice** for the continuous prophylaxis of migraine. It is a non-selective beta-blocker that works by stabilizing vascular tone, reducing central catecholaminergic hyperactivity, and inhibiting the cortical spreading depression (CSD) associated with migraine pathophysiology. It is particularly effective in patients with co-existing hypertension or anxiety. **Analysis of Options:** * **A. Sumatriptan:** This is a 5-HT$_{1B/1D}$ receptor agonist used for the **acute treatment** of migraine attacks to abort the headache. It is never used for prophylaxis because frequent use can lead to "medication overuse headache." * **C. Valproate:** While sodium valproate is an effective prophylactic agent (especially for patients with comorbid epilepsy), it is generally considered a second-line option due to its side-effect profile (weight gain, hair loss, and teratogenicity). * **D. Flunarizine:** This is a calcium channel blocker used for prophylaxis, particularly in Europe and India. However, due to its side effects (sedation and weight gain) and slower onset of action, it is usually not the first choice over beta-blockers. **High-Yield Clinical Pearls for NEET-PG:** * **Prophylaxis Criteria:** Indicated if attacks occur $>2-3$ times per month or are severely disabling. * **Contraindications for Propranolol:** Avoid in patients with bronchial asthma, heart block, or peripheral vascular disease (Raynaud’s). * **Other Prophylactic Agents:** Amitriptyline (DOC if comorbid depression/insomnia), Topiramate (DOC if the patient is obese, as it causes weight loss), and CGRP antagonists (e.g., Erenumab) for refractory cases. * **DOC in Pregnancy:** Magnesium or low-dose Propranolol (though lifestyle changes are preferred). Avoid Valproate (Category X for migraine).

Question 134: Which of the following is an example of a long-acting neuromuscular blocker?

A. Rocuronium
B. Vecuronium
C. Pancuronium (Correct Answer)
D. Atracurium

Explanation: **Explanation:** Neuromuscular blocking agents (NMBAs) are classified based on their chemical structure and, more clinically relevant for the NEET-PG, their **duration of action**. **1. Why Pancuronium is Correct:** **Pancuronium** is a long-acting, non-depolarizing steroid-based NMBA. It typically has a duration of action exceeding **60–90 minutes**. It is primarily excreted by the kidneys, meaning its action is significantly prolonged in patients with renal failure. **2. Analysis of Incorrect Options:** * **Rocuronium (Option A):** An intermediate-acting steroid derivative. It is highly high-yield because it has the **fastest onset of action** (60–90 seconds) among non-depolarizing blockers, making it an alternative to Succinylcholine for Rapid Sequence Induction (RSI). * **Vecuronium (Option B):** An intermediate-acting steroid derivative (duration ~30–40 minutes). It is noted for its cardiovascular stability. * **Atracurium (Option D):** An intermediate-acting benzylisoquinoline. It is unique because it undergoes **Hofmann elimination** (spontaneous degradation in plasma), making it the drug of choice in patients with liver or kidney failure. **3. High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Long-acting:** "Pipe and Pan" (**Pipecuronium** and **Pancuronium**). * **Vagolytic Effect:** Pancuronium causes tachycardia by blocking muscarinic receptors in the heart; avoid in patients where tachycardia is detrimental. * **Drug of Choice in Renal/Hepatic Failure:** Atracurium or **Cisatracurium** (Cisatracurium is more potent and produces less histamine). * **Shortest Acting NMBA:** **Succinylcholine** (Depolarizing) or **Gantacurium** (Non-depolarizing, ultra-short). * **Reversal Agent:** Sugammadex is specifically used to reverse steroid-based NMBAs (Rocuronium > Vecuronium > Pancuronium).

Question 135: Vasomotor reversal of Dale is demonstrated by

A. Fall in blood pressure by high dose intravenous Acetylcholine
B. Increase in blood pressure following administration of IV propranolol
C. Fall in blood pressure by a ganglionic blocker
D. Fall in blood pressure by adrenaline pretreated with phentolamine (Correct Answer)

Explanation: ### Explanation **Vasomotor Reversal of Dale** is a classic pharmacological phenomenon that demonstrates the dual action of Adrenaline on alpha ($\alpha$) and beta ($\beta$) receptors. #### Why the Correct Answer is Right Adrenaline is a non-selective adrenergic agonist. Under normal conditions, its effect on **$\alpha_1$ receptors** (vasoconstriction) is more potent than its effect on **$\beta_2$ receptors** (vasodilation), leading to a net **rise** in blood pressure. When a patient is pretreated with an $\alpha$-blocker like **Phentolamine**, the $\alpha_1$-mediated vasoconstriction is abolished. This "unmasks" the $\beta_2$ receptors. Subsequent administration of Adrenaline then acts only on $\beta_2$ receptors, causing peripheral vasodilation and a paradoxical **fall** in blood pressure. This reversal from a pressor to a depressor response is Dale's phenomenon. #### Why Other Options are Wrong * **Option A:** Acetylcholine naturally causes a fall in BP via M3 receptors (NO release). This is its standard action, not a "reversal." * **Option B:** Propranolol is a $\beta$-blocker. While it may cause a slight rise in BP due to unopposed $\alpha$-action if catecholamines are present, it does not demonstrate Dale's reversal. * **Option C:** Ganglionic blockers (e.g., Hexamethonium) reduce BP by blocking sympathetic tone, which is their primary expected mechanism. #### High-Yield Clinical Pearls for NEET-PG * **Specific to Adrenaline:** This reversal is **not** seen with Noradrenaline (lacks significant $\beta_2$ action) or Phenylephrine (pure $\alpha$ agonist). * **Clinical Significance:** If a patient with Pheochromocytoma is given a $\beta$-blocker before an $\alpha$-blocker, it can lead to a hypertensive crisis (the opposite of Dale's phenomenon) due to unopposed $\alpha$-vasoconstriction. * **Key Receptors:** Remember: $\alpha_1$ = Constriction; $\beta_2$ = Dilation. Dale's reversal = $\alpha$ blocked, $\beta_2$ unmasked.

Question 136: Maximum duration of action is seen with which of the following drugs?

A. Atracurium
B. Rocuronium
C. Pancuronium (Correct Answer)
D. Rapcuronium

Explanation: **Explanation:** The duration of action of neuromuscular blocking agents (NMBAs) is primarily determined by their chemical structure and metabolism. NMBAs are classified into short, intermediate, and long-acting agents. **Why Pancuronium is correct:** Pancuronium is a long-acting, non-depolarizing neuromuscular blocker of the aminosteroid group. It has a duration of action typically ranging from **60 to 120 minutes**. Its long half-life is due to its reliance on renal excretion (approx. 80%) and minimal hepatic metabolism. In the context of the options provided, it has the longest duration. **Analysis of incorrect options:** * **Atracurium:** This is an intermediate-acting benzylisoquinolone. It has a duration of **30–45 minutes**. It is unique because it undergoes **Hofmann elimination** (spontaneous non-enzymatic degradation), making it safe in renal or hepatic failure. * **Rocuronium:** This is an intermediate-acting aminosteroid with a duration of **30–40 minutes**. It is favored for its rapid onset of action, making it an alternative to Succinylcholine for rapid sequence intubation. * **Rapcuronium:** This was a short-acting agent (duration **15–20 minutes**) but was withdrawn from the market due to the high risk of severe bronchospasm. **High-Yield Clinical Pearls for NEET-PG:** * **Longest acting NMBA:** Doxacurium (Pipecuronium and Pancuronium are also in the long-acting category). * **Shortest acting non-depolarizing NMBA:** Mivacurium (metabolized by plasma cholinesterase). * **Drug of choice in Renal Failure:** Atracurium or Cisatracurium (due to Hofmann elimination). * **Vagolytic effect:** Pancuronium can cause tachycardia by blocking muscarinic receptors in the heart. * **Specific Reversal Agent:** Sugammadex is used specifically for aminosteroids (Rocuronium > Vecuronium > Pancuronium).

Question 137: Which antiglaucoma drugs are safe to use in a patient with asthma?

A. Timolol
B. Betaxolol (Correct Answer)
C. Propranolol
D. All the above

Explanation: The primary concern when using beta-blockers in patients with asthma is the risk of **bronchospasm**. This occurs due to the blockade of **β$_2$ receptors** in the bronchial smooth muscle, which normally mediate bronchodilation. **1. Why Betaxolol is the correct answer:** Betaxolol is a **cardioselective (β$_1$ selective)** adrenoceptor antagonist [1, 2]. Because it primarily targets β$_1$ receptors (found mainly in the heart) and has minimal affinity for β$_2$ receptors, it is significantly safer for the respiratory system [1]. While no beta-blocker is 100% safe in severe asthma, betaxolol is the preferred topical beta-blocker when such therapy is necessary for a patient with reactive airway disease [1]. **2. Why the other options are incorrect:** * **Timolol:** This is a **non-selective** beta-blocker (β$_1$ + β$_2$) [1]. Even when administered topically as eye drops, systemic absorption via the nasolacrimal duct can cause life-threatening bronchospasm in asthmatic patients. It is the most common antiglaucoma drug associated with this side effect [1]. * **Propranolol:** This is a prototypical non-selective beta-blocker [1]. It is not used topically for glaucoma and is strictly contraindicated in asthma due to its potent β$_2$ blocking effects [1]. **Clinical Pearls for NEET-PG:** * **Mechanism in Glaucoma:** Beta-blockers reduce intraocular pressure (IOP) by **decreasing the production of aqueous humor** from the ciliary body [1]. * **Systemic Absorption:** To minimize systemic side effects of eye drops, advise patients to perform **nasolacrimal occlusion** (pressing the inner corner of the eye) for 1-2 minutes after instillation. * **Other Safe Alternatives:** In asthmatics, if beta-blockers are risky, consider **Prostaglandin analogues** (Latanoprost) or **Carbonic anhydrase inhibitors** (Dorzolamide).

Question 138: Which drugs would antagonize the interaction of catecholamines with adrenergic receptors?

A. Methyldopa
B. Clonidine
C. Phenylephrine
D. Yohimbine (Correct Answer)

Explanation: **Explanation:** The question asks for a drug that **antagonizes** (blocks) the interaction of catecholamines with adrenergic receptors. **1. Why Yohimbine is Correct:** Yohimbine is a selective **$\alpha_2$-adrenergic receptor antagonist**. By binding to these receptors, it prevents catecholamines (like norepinephrine) from interacting with them. While it was historically used for erectile dysfunction, its clinical use is now limited. In pharmacology, it serves as the classic prototype for $\alpha_2$ blockade. **2. Why the Other Options are Incorrect:** * **Methyldopa:** This is a centrally acting **sympatholytic**, but it does not act as a receptor antagonist. It is a prodrug converted to $\alpha$-methylnorepinephrine, which acts as an **agonist** at central $\alpha_2$ receptors to decrease sympathetic outflow. * **Clonidine:** This is a selective **$\alpha_2$-receptor agonist**. It stimulates presynaptic receptors in the brainstem, leading to a reduction in peripheral sympathetic tone. It is used in hypertension and opioid withdrawal. * **Phenylephrine:** This is a selective **$\alpha_1$-receptor agonist**. It mimics the action of catecholamines to cause vasoconstriction and mydriasis; it does not antagonize them. **High-Yield Clinical Pearls for NEET-PG:** * **$\alpha$-Blocker Classification:** Remember **Phentolamine** (Non-selective), **Prazosin** (Selective $\alpha_1$), and **Yohimbine** (Selective $\alpha_2$). * **Reversal of Action:** $\alpha$-blockers can cause "Dale’s Vasomotor Reversal," where the pressor effect of adrenaline is converted to a depressor effect. * **Drug of Choice:** Methyldopa remains a preferred drug for **hypertension in pregnancy** (along with Labetalol and Hydralazine). * **Clonidine Side Effect:** Sudden withdrawal can lead to **rebound hypertension** due to a sympathetic surge.

Question 139: Cinnarizine, used for motion sickness, is a:

A. 5HT4 antagonist
B. H1 antagonist (Correct Answer)
C. Antihistamine
D. NK1 antagonist

Explanation: **Explanation:** **Cinnarizine** is a piperazine derivative that primarily acts as a **sedating H1 receptor antagonist**. Its efficacy in motion sickness is attributed to its ability to inhibit the vestibular system. It suppresses the stimulation of the labyrinth by blocking H1 receptors in the vestibular nuclei and the chemoreceptor trigger zone (CTZ), thereby preventing nausea, vomiting, and vertigo. **Analysis of Options:** * **Option B (H1 antagonist):** This is the most specific pharmacological classification. Cinnarizine blocks H1 receptors and also possesses weak anticholinergic and calcium channel blocking properties, which contribute to its anti-vertigo effects. * **Option A (5HT4 antagonist):** 5HT4 receptors are primarily involved in gastrointestinal motility (prokinetics). Drugs like Prucalopride act here; Cinnarizine has no significant activity at this receptor. * **Option C (Antihistamine):** While Cinnarizine is an antihistamine, in competitive exams like NEET-PG, if both "Antihistamine" and "H1 antagonist" are provided, **H1 antagonist** is the more precise pharmacological description of its mechanism. * **Option D (NK1 antagonist):** Neurokinin-1 (NK1) antagonists, such as **Aprepitant**, are used for chemotherapy-induced nausea and vomiting (CINV), not typically for motion sickness. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC) for Motion Sickness (Prophylaxis):** Hyoscine (Scopolamine) is the most effective, usually administered as a transdermal patch. * **Cinnarizine’s Unique Property:** It is also a **T-type calcium channel blocker**, which helps in improving peripheral circulation and is used in Meniere’s disease. * **Side Effects:** Significant sedation and, with chronic use in the elderly, **drug-induced parkinsonism** (due to weak D2 blocking activity).

Question 140: Neostigmine used in the treatment of myasthenia gravis acts by:

A. Increasing the number of receptors for acetylcholine
B. Increasing synthesis of acetylcholine
C. Decreasing breakdown of acetylcholine (Correct Answer)
D. Increasing acetylcholine degradation

Explanation: **Explanation:** **Mechanism of Action (Why C is correct):** Neostigmine is a **reversible anticholinesterase** agent. In Myasthenia Gravis (MG), there is a functional deficiency of nicotinic acetylcholine receptors (Nm) at the neuromuscular junction due to autoantibodies. Neostigmine acts by inhibiting the enzyme **Acetylcholinesterase (AChE)**, which is responsible for the hydrolysis of acetylcholine (ACh). By blocking this enzyme, Neostigmine prevents the breakdown of ACh, leading to an increased concentration and prolonged persistence of ACh in the synaptic cleft. This allows the available ACh to compete more effectively for the remaining functional receptors, thereby improving muscle strength. **Analysis of Incorrect Options:** * **Option A:** Neostigmine does not increase the number of receptors; it maximizes the utility of existing ones. * **Option B:** It has no direct effect on the choline acetyltransferase enzyme or the rate of ACh synthesis. * **Option D:** This is the opposite of its pharmacological effect; increasing degradation would worsen myasthenic symptoms. **High-Yield Clinical Pearls for NEET-PG:** * **Quaternary Ammonium Structure:** Neostigmine is a polar compound; it **does not cross the Blood-Brain Barrier (BBB)**, making it ideal for peripheral action without CNS side effects. * **Direct Action:** Unlike physostigmine, neostigmine also has a small **direct agonist effect** on nicotinic receptors. * **Drug of Choice:** It is commonly used for the symptomatic treatment of MG and for reversing the effect of non-depolarizing muscle relaxants (e.g., d-Tubocurarine). * **Side Effects:** Muscarinic effects (miosis, bradycardia, salivation) are common and can be managed with **Atropine**.

Practice by Chapter

Cholinergic Agonists

Practice Questions

Cholinergic Antagonists

Practice Questions

Adrenergic Agonists

Practice Questions

Adrenergic Antagonists

Practice Questions

Ganglionic Agents

Practice Questions

Neuromuscular Blocking Agents

Practice Questions

Autonomic Drugs in Ophthalmology

Practice Questions

Autonomic Drugs in Cardiovascular Disease

Practice Questions

Autonomic Drugs in Respiratory Disease

Practice Questions

Autonomic Drugs in Urological Disorders

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free